Surgical Management of Jugular Foramen Schwannomas

Standard

Surgical Management of Jugular Foramen Schwannomas. / Aftahy, Amir Kaywan; Groll, Maximilian; Barz, Melanie; Bernhardt, Denise; Combs, Stephanie E; Meyer, Bernhard; Negwer, Chiara; Gempt, Jens.

In: CANCERS, Vol. 13, No. 16, 4218, 22.08.2021.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

Aftahy, AK, Groll, M, Barz, M, Bernhardt, D, Combs, SE, Meyer, B, Negwer, C & Gempt, J 2021, 'Surgical Management of Jugular Foramen Schwannomas', CANCERS, vol. 13, no. 16, 4218. https://doi.org/10.3390/cancers13164218

APA

Aftahy, A. K., Groll, M., Barz, M., Bernhardt, D., Combs, S. E., Meyer, B., Negwer, C., & Gempt, J. (2021). Surgical Management of Jugular Foramen Schwannomas. CANCERS, 13(16), [4218]. https://doi.org/10.3390/cancers13164218

Vancouver

Aftahy AK, Groll M, Barz M, Bernhardt D, Combs SE, Meyer B et al. Surgical Management of Jugular Foramen Schwannomas. CANCERS. 2021 Aug 22;13(16). 4218. https://doi.org/10.3390/cancers13164218

Bibtex

@article{601da51c5328470bb0190e4e535ef8c2,
title = "Surgical Management of Jugular Foramen Schwannomas",
abstract = "BACKGROUND: Resection of jugular foramen schwannomas (JFSs) with minimal cranial nerve (CN) injury remains difficult. Reoperations in this vital region are associated with severe CN deficits.METHODS: We performed a retrospective analysis at a tertiary neurosurgical center of patients who underwent surgery for JFSs between June 2007 and May 2020. We included nine patients (median age 60 years, 77.8% female, 22.2% male). Preoperative symptoms included hearing loss (66.6%), headache (44.4%), hoarseness (33.3%), dysphagia (44.4%), hypoglossal nerve palsy (22.2%), facial nerve palsy (33.3%), extinguished gag reflex (22.2%), and cerebellar dysfunction (44.4%). We observed Type A, B, C, and D tumors in 3, 1, 1, and 4 patients, respectively. A total of 77.8% (7/9) underwent a retrosigmoid approach, and 33.3% (3/9) underwent an extreme lateral infrajugular transcondylar (ELITE) approach. Gross total resection (GTR) was achieved in all cases. The rate of shunt-dependent hydrocephalus was 22.2% (2/9). No further complications requiring surgical intervention occurred during follow-up. The median follow-up time was 16.5 months (range 3-84 months).CONCLUSIONS: Considering the satisfying outcome, the GTR of JFSs is feasible in performing well-known skull base approaches. Additional invasive and complicated approaches were not needed. Radiosurgery may be an effective alternative for selected patients.",
author = "Aftahy, {Amir Kaywan} and Maximilian Groll and Melanie Barz and Denise Bernhardt and Combs, {Stephanie E} and Bernhard Meyer and Chiara Negwer and Jens Gempt",
year = "2021",
month = aug,
day = "22",
doi = "10.3390/cancers13164218",
language = "English",
volume = "13",
journal = "CANCERS",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "16",

}

RIS

TY - JOUR

T1 - Surgical Management of Jugular Foramen Schwannomas

AU - Aftahy, Amir Kaywan

AU - Groll, Maximilian

AU - Barz, Melanie

AU - Bernhardt, Denise

AU - Combs, Stephanie E

AU - Meyer, Bernhard

AU - Negwer, Chiara

AU - Gempt, Jens

PY - 2021/8/22

Y1 - 2021/8/22

N2 - BACKGROUND: Resection of jugular foramen schwannomas (JFSs) with minimal cranial nerve (CN) injury remains difficult. Reoperations in this vital region are associated with severe CN deficits.METHODS: We performed a retrospective analysis at a tertiary neurosurgical center of patients who underwent surgery for JFSs between June 2007 and May 2020. We included nine patients (median age 60 years, 77.8% female, 22.2% male). Preoperative symptoms included hearing loss (66.6%), headache (44.4%), hoarseness (33.3%), dysphagia (44.4%), hypoglossal nerve palsy (22.2%), facial nerve palsy (33.3%), extinguished gag reflex (22.2%), and cerebellar dysfunction (44.4%). We observed Type A, B, C, and D tumors in 3, 1, 1, and 4 patients, respectively. A total of 77.8% (7/9) underwent a retrosigmoid approach, and 33.3% (3/9) underwent an extreme lateral infrajugular transcondylar (ELITE) approach. Gross total resection (GTR) was achieved in all cases. The rate of shunt-dependent hydrocephalus was 22.2% (2/9). No further complications requiring surgical intervention occurred during follow-up. The median follow-up time was 16.5 months (range 3-84 months).CONCLUSIONS: Considering the satisfying outcome, the GTR of JFSs is feasible in performing well-known skull base approaches. Additional invasive and complicated approaches were not needed. Radiosurgery may be an effective alternative for selected patients.

AB - BACKGROUND: Resection of jugular foramen schwannomas (JFSs) with minimal cranial nerve (CN) injury remains difficult. Reoperations in this vital region are associated with severe CN deficits.METHODS: We performed a retrospective analysis at a tertiary neurosurgical center of patients who underwent surgery for JFSs between June 2007 and May 2020. We included nine patients (median age 60 years, 77.8% female, 22.2% male). Preoperative symptoms included hearing loss (66.6%), headache (44.4%), hoarseness (33.3%), dysphagia (44.4%), hypoglossal nerve palsy (22.2%), facial nerve palsy (33.3%), extinguished gag reflex (22.2%), and cerebellar dysfunction (44.4%). We observed Type A, B, C, and D tumors in 3, 1, 1, and 4 patients, respectively. A total of 77.8% (7/9) underwent a retrosigmoid approach, and 33.3% (3/9) underwent an extreme lateral infrajugular transcondylar (ELITE) approach. Gross total resection (GTR) was achieved in all cases. The rate of shunt-dependent hydrocephalus was 22.2% (2/9). No further complications requiring surgical intervention occurred during follow-up. The median follow-up time was 16.5 months (range 3-84 months).CONCLUSIONS: Considering the satisfying outcome, the GTR of JFSs is feasible in performing well-known skull base approaches. Additional invasive and complicated approaches were not needed. Radiosurgery may be an effective alternative for selected patients.

U2 - 10.3390/cancers13164218

DO - 10.3390/cancers13164218

M3 - SCORING: Journal article

C2 - 34439372

VL - 13

JO - CANCERS

JF - CANCERS

SN - 2072-6694

IS - 16

M1 - 4218

ER -